- Flamma has won a 2025 CDMO Leadership Award in the Small Molecule API – Global category.
- The award, presented by Outsourced Pharma, is based on real customer feedback from nearly 300 survey respondents.
Flamma, a global contract development and manufacturing organisation (CDMO) specialising in small molecule APIs, has been named a winner in the 2025 CDMO Leadership Awards. The company was recognised in the Small Molecule API – Global category, reinforcing its position as a key player in pharmaceutical outsourcing.
Now in its 14th year, the CDMO Leadership Awards, organised by Outsourced Pharma, evaluates CDMOs based on customer feedback. This year, nearly 300 industry professionals assessed 210 CDMOs, focusing on their performance over the past 24 months. The awards use a refined scoring methodology, developed in collaboration with Orientation Marketing, to rank companies across four categories: Small Molecule API, Biologics, Cell & Gene Therapy, and Small Molecule Dosage Form. These are further divided into Global, North American, and International service regions.
Flamma’s recognition in the Small Molecule API – Global category highlights its expertise in developing and manufacturing new chemical entities (NCEs) and late-stage intermediates for pharmaceutical innovators.
Expressing gratitude for the honour, Kenneth Drew, Ph.D., VP of Flamma USA, stated: “Flamma would like to express strong gratitude to Outsourced Pharma for continuing to shine a light and recognising deserving CDMOs for their tireless work to help innovator companies in Biotech and Pharma who are trying to bring new medicines to the world.” He also acknowledged the support of customers who participated in the survey.
As Flamma marks 75 years of service in the pharmaceutical industry, this award underscores its ongoing commitment to excellence in contract manufacturing and API development.
Stay ahead of trends and best practices
